NAV
Explore a selection of essential drug information below, or:
Unlock enhanced features & extensive drug insights. Create a free account.
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Flotetuzumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Explore a selection of our essential drug information below, or:

CREATE FREE ACCOUNT
Full Drug Profiles
Unlock enhanced features & extensive drug insights, including detailed interaction data & regulatory status. Create a free account.
SUBSCRIBERECOMMENDED FOR PHARMA
Data Packages
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Identification

Generic Name
Flotetuzumab
DrugBank Accession Number
DB15223
Background

Flotetuzumab is under investigation in clinical trial NCT02152956 (Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS).

Type
Biotech
Groups
Investigational
Synonyms
  • Flotetuzumab
Unlock the secrets to drugging the undruggable
Discover how groundbreaking research is turning "undruggable" targets into therapeutic opportunities.
Download eBook
Unlock the secrets to drugging the undruggable
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
0AHT0IC02G
CAS number
1664355-28-5

References

General References
Not Available
Wikipedia
Flotetuzumab

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
Unlock 175K+ rows when you subscribe.View sample data
Not AvailableNo Longer AvailableNot AvailableAcute Myeloid Leukemia / AML, Adult Recurrent1somestatusstop reasonjust information to hide
2TerminatedTreatmentRelapsed Acute Myelogenous Leukemia (AML)1somestatusstop reasonjust information to hide
2WithdrawnTreatmentAcute Biphenotypic Leukemia (ABL) / Acute Leukemia / Hairy Cell Leukemia (HCL) / Interleukin-3 Receptor Subunit Alpha Positive / Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML) / Recurrent Acute Lymphoblastic Leukemia (ALL) / Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Hematologic Malignancy / Recurrent Hodgkin Lymphoma / Refractory Acute Lymphoblastic Leukemia (ALL) / Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm / Refractory Hematologic Malignancy / Refractory Hodgkin Lymphoma / Systemic Mastocytosis1somestatusstop reasonjust information to hide
2WithdrawnTreatmentAcute Myeloid Leukemia1somestatusstop reasonjust information to hide
1Active Not RecruitingTreatmentRecurrent Acute Leukemia / Recurrent B Acute Lymphoblastic Leukemia / Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Hairy Cell Leukemia / Recurrent Hematologic Malignancy / Recurrent Hodgkin Lymphoma / Recurrent T-cell Acute Lymphoblastic Leukemia / Refractory Acute Leukemia / Refractory B Cell Acute Lymphoblastic Leukemia (ALL) / Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Hairy Cell Leukemia / Refractory Hematologic Malignancy / Refractory Hodgkin Lymphoma / Refractory T-cell Acute Lymphoblastic Leukemia / Systemic Mastocytosis1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at May 20, 2019 15:01 / Updated at February 21, 2021 18:55